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E-mail address: Hongquan.Zhang@bjmu.edu.cn (HFERM family proteins have been known to play an important role in tumor progression. FERM-
domain containing protein 5 (FRMD5), a novel putative cytoskeletal protein, is an unknown func-
tion protein. Here, we reported that FRMD5 localized at the cell adherens junction and formed a
molecular complex with p120-catenin through its C-terminal region. Functionally, we found that
knockdown of endogenous FRMD5 promotes lung cancer cell migration and invasion in vitro as well
as tumor growth in vivo, suggesting a tumor suppressive effect. These ﬁndings indicated that FRMD5
may play a role in p120-catenin-based cell–cell contact and is involved in the regulation of tumor
progression.
Structured summary of protein interactions
FRMD5 and p120 catenin colocalize by ﬂuorescence microscopy (View interaction)
FRMD5 physically interacts with p120 catenin by anti tag coimmunoprecipitation (View interaction)
FRMD5 and Beta-catenin colocalize by ﬂuorescence microscopy (View interaction)
FRMD5 and gamma-catenin colocalize by ﬂuorescence microscopy (View interaction)
FRMD5 physically interacts with p120 catenin and E cadherin by anti bait coimmunoprecipitation (View
interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Tumor progression is a multi-stepped process, which is char-
acterized by migration and invasion. Many molecules are in-
volved in the regulation of the complicated process, such as
FERM superfamily members [1]. The members of this superfamily
contain a conserved FERM (stands for protein Four point one, Ez-
rin, Radixin and Moesin) domain, which is composed of three
sub-domains: FERM-N, FERM-M and FERM-C. Although these
sub-domains are folded independently, they are closely associ-
ated with each other by forming a cloverleaf conﬁguration [2].
In human, this superfamily has about 50 members and was di-
vided into six subgroups including FERM-FA, ERM, MyTh-myosin,
FERM proteins at cell–ECM contacts, Janus kinases and other
FERM-FA subgroup [2]. The FA (FERM-adjacent) domain is foldedchemical Societies. Published by E
y, Histology and Embryology,
Yuan Road, Beijing 100191,
. Zhang).by elements of a and b structure, containing the sites of phospho-
rphorylation induced by protein kinase A and C [3]. FERM-FA sub-
group includes the ﬁrst identiﬁed FERM protein 4.1R [4], which
binds to various membrane components and cytoskeletal mole-
cules to stabilize the membrane structure of red blood cells. Inac-
tivation of protein 4.1R has been found in some tumors such as
meningiomas [5], neuroblastomas [6] and ependymomas [7].
Moreover, many other FERM-FA family proteins, such as protein
4.1B and FRMD3 [8], have been identiﬁed as tumor suppressors.
Protein 4.1B was ﬁrstly found as a suppressor of lung cancer
[9], followed in brain [10], breast [11], renal [12] and prostate
[13] cancers. Loss of DAL-1, the truncated protein 4.1B, is an
important early event in meningioma tumorigenesis [14]. How-
ever, EPB41L5, another FERM-FA family member, plays a positive
role in the process of epithelial-to-mesenchymal transition (EMT).
EPB41L5 interacts with p120-catenin through its N-terminal
FERM domain, and inhibits the binding of p120-catenin to E-cad-
herin, resulting in the decrease of E-cadherin. Moreover, EPB41L5
is also associated with paxillin to promote the formation of focal
adhesion [15].lsevier B.V. All rights reserved.
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been reported as a potential target of p53 (R273H) in U251 glioblas-
toma [16], and is downregulated in side population (SP) cells from
A549 cells compared to non-SP cells [17]. These ﬁndings imply that
the biological function of FRMD5 is related to tumor progression.
However, few reports identiﬁed the biological function of FRMD5
and the relationship between FRMD5 and tumor progression. Here,
we found that FRMD5 is localized at the cell-cell contact, and inter-
acts with p120-catenin, participating in the cell adherens junction.
Functionally, we found FRMD5 not only suppresses cell migration
and invasion in the lung cancer cells H1299, but also inhibits
tumorigenesis in the nude mice. Taken together, FRDM5 is identi-
ﬁed as a FERM domain-containing novel tumor suppressive
molecule.
2. Materials and methods
2.1. Animals and cell lines
Female BALB/c nude mice of 4–6 weeks old were purchased
from the Animal Department of Peking University Health Science
Center (Beijing, PRC) for studies approved by the Animal Care
and Use Committee of Peking University Health Science Center.
The H1299, A549, Wart, U1752, U1810, U1906, Colo320, SW620,
SW480, LST, SW1116, RKO, HT29, HCT116 and HeLa cell lines were
cultured in RPMI 1640 and DMEM medium (Invitrogen, Carlsbad,
CA) containing 10% FBS (Hyclone), 100 IU/ml of penicillin and
100 lg/ml of streptomycin respectively. The cells were cultured
at 37 C with 5% CO2 in a humidiﬁed incubator.
2.2. RNA interference
FRMD5 small interfering RNAs were designed according to the
human FRMD5 cDNA sequence, targeting at the regions of
326–344, 543–561, 595–613 counted from the start codon ATG,
with the sense targeting sequence: CCAGGTATTTAGTCTTCCT,
GGAACTGAGTGGTCAAACA, GCACAGACATTGGAAACAT synthesized
by GenePharma. An irrelevant chemically synthesized control siR-
NA was obtained from Qiagen.
FRMD5 shRNA were constructed according to HuSH™ shRNA
plasmids (29-mer) APPLICATION GUIDE. The oligonucleotides were
synthesized by AuGCT with the sequences getting from the web-
site http://www.origene.com/rnai/quality.mspx. sh-FRMD5 with
the sense target sequence: ACAGCGAGTACACCTGCACCAT CCAGA-
GA, sh-FRMD5a with the sense target sequence: AGTGGTCAAA
CACCAGCAACATCAGAGC.
2.3. Stable transfection of sh-FRMD5 and sh-NC
Transient transfection was done according to the guide lines of
Lipofectamine 2000 transfection reagent. After H1299 cells were
transfected with sh-FRMD5, sh-FRMD5a and sh-NC for 24 h, cells
were passaged and inoculated into 6-well plate. Stable clones were
selected by 0.4 lg/ml Puromysin (Gibco) for two months. The GFP
ﬂuorescence was nearly 100% using ﬂuorescence microscope and
lasted for 2 weeks, the cells were cultured in the medium
mentioned above with addition of 0.1 lg/ml Puromysin for
maintenance.
2.4. Western blot
Total cell lysates were extracted using PBSTDS lysis buffer con-
taining 1  cocktail inhibitor. Equal amount (20 lg) of cell lysates
were mixed with SDS loading buffer and separated on 10% SDS–
PAGE gels. Transfered membrane was blocked with 5% milk in
TBST buffer for 2 h and immunoblotted with anti-FRMD5 antibody(Sigma), anti-E-cadherin (Epitomics), anti-b-actin (Zhongshan
golden bridge), anti-vimentin (Santa cruz), at 1:1,000 dilution
overnight. HRP-Goat-anti-Mouse IgG and anti-Rabbit IgG (Zhong-
shan golden bridge) at 1:5,000 dilutions were used as secondary
antibodies and applied for 40 min. Immobilized antibodies were
then detected by enhanced chemiluminescence (Thermo).
2.5. Immunoﬂuorescence assay
H1299 cells were ﬁxed in 4% paraformaldehyde for 15 min at
room temperature, permeabilized with 0.5% Triton X-100 for
15 min and blocked in 1% BSA for 1.5 h in 0.01 M PBS. Then, cells
were incubated with primary antibodies diluted in the blocking
buffer overnight. Subsequently, cells were washed three times
with PBS, incubated with appropriate ﬂuorochrome-conjugated
secondary antibodies for 40 min and washed 3 times with PBS. Nu-
clei were stained by DAPI for 1 min and washed 3 times with PBS.
Then cells were mounted with antifade solution.
2.6. Co-IP
Total cell lysates were extracted using NP-40 buffer for 30 min
on ice, and then they were centrifuged at 12,000g for 15 min at
4 C. 500 lg of protein was incubated with speciﬁc antibodies
and protein A or G agarose beads for 4 h at 4 C, and centrifuged
at 500g for 2 min. The supernatant was collected and incubated
with speciﬁc antibodies overnight at 4 C with constant rotation
for immunoprecipitation. Protein A or G agarose beads were then
added and incubated for another 4 h. Then the beads were washed
three times using the lysis buffer. 2  SDS–PAGE loading buffer
was added to the mixture, and boiled for 5 min.
2.7. Wound healing assays and Transwell assay
Wound healing assays were also performed 48 h after seeding
the stably transfected cells. A standard 100 ll pipette tip was used
to produce a wound approximately 400 lm wide. The monolayers
were then washed twice to remove non-adherent cells and the
migration ability of the cells was evaluated by measuring relative
velocity of wound closure. Transwell migration and invasion assays
were performed using Transwell chambers (Costar) with 8.0 lm
pore size. The lower surface of the Transwell membrane was im-
mersed to RPMI 1640 with 20% FBS. 3  104 H1299 cells which sta-
bly transfected with sh-FRMD5 and control sh-RNA, were seeded
on the upper surface of the Transwell membranes (for invasion as-
say, Matrigel was pre-coated), followed by 6 h incubation (for inva-
sion assay, 48 h incubation) at 37 C in RPMI 1640 with 1% FBS. The
Transwell membrane was then ﬁxed with 4% formaldehyde for
30 min and stained by crystal violet. Eighteen microscopic ﬁelds
were randomly chosen for analyses.
2.8. Nude mouse transplantation tumor experiment
4  106 H1299 sh-FRMD5 and sh-NC cells were counted and
resuspended with 100 ll PBS, respectively. The cells were then in-
jected subcutaneously into the armpit of 4-week-old female nude
mice (Center of Experimental Animals, Peking University, Beijing,
China), which were executed 3 weeks after implantation. The mice
were maintained according to the Guidelines of Animal Experi-
ments by Peking University.
2.9. Ethics
The local Ethics Committee approved this study. The procedures
followed were in accordance with the ethical standard of the Hel-
sinki Declaration of 1975, as revised in 1983.
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3.1. Cloning and characterization of FRMD5
FERM domain containing protein 5 (FRMD5, NCBI gene ID:
84978) is located on chromosome 15q15.3, encoding a 570-amino
acid protein. As FRMD5 shares 51% sequence similarity and highly
conserved with FRMD3, phylogenetic analysis was carried out with
the amino acid sequences of orthologous genes of FRMD3 and
FRMD5. The phylogenetic tree was calculated based on the neigh-
bor-joining method (Fig. 1A). Bioinformatic analysis indicates that,
similar to FRMD3, FRMD5 is composed of FERM-N, FERM-M, FERM-
C and FA domain (Fig, 1B). Protein scheme was generated by
DOG2.0 software [18]. Both phylogenetic tree and bioinformaticFig. 1. Characterization of FRMD5. (A). The evolutionary history of FRMD5 inferred by
FRMD5 constructs used in this study. FRMD5 contains four conserved domains: FERM-N
aa). We divided FRMD5 into two different parts. The N-terminal region of FRMD5 cont
contains no well known domain. (C) FRMD5 gene centric expression analysis revealed by
carcinomas relative to normal colon (P = 0.0007) and breast (P = 0.0086) tissues. (D) FR
highly in corresponding non-tumor tissues. b. FRMD5 rarely expressed in tumor tissues.
cancer cell lines.analysis indicated that the biological function of FRMD5 may be
similar to FRMD3.
Further, to explore the relationship between FRMD5 and tumor
progression, we searched the Oncomine database. Available micro-
array data showed that FRMD5 was downregulated in colorectal
and mucinous breast carcinoma, compared to normal tissue
(Fig. 1C). Moreover, a correlation between FRMD5 and renal carci-
noma was explored in patients. We found that the expression level
of FRMD5 is low in renal carcinoma compared to carcinoma side
tissues (3/3 of carcinoma side and 0/9 of renal carcinoma tissues
showed positive reaction) by immunohistochemistry assays
(Fig. 1D). These data indicated that the level of FRMD5 is relatively
low in colonrectal cancer, mucinous breast cancer and renal cancer,
and suggested that FRMD5 is an inhibitory protein in tumor.using neighbor-joining method. (B) Schematic representation of protein domains
(21–98 aa), FERM-M (104–210 aa), FERM-C (204–295 aa) and FA domain (308–354
ains FERM-N, FERM-M, FERM-C and FA domains. The C-terminal region of FRMD5
Oncomine. FRMD5 is down-regulated in a subset of colorectal and mucinous breast
MD5 expression levels examined by immunohistochemistry. a. FRMD5 expressed
(E) The expressing proﬁle of FRMD5 was quantiﬁed by western blotting in six lung
Fig. 2. FRMD5 localized to the cell–cell contact. (A) GFP-tagged FRMD5 (green) was expressed in HeLa cells, F-actin was stained by Phalloidin (red), and nuclei were stained
by DAPI (blue). The three arrows showed GFP-FRMD5 localized in the cell–cell contact. (B) GFP-tagged FRMD5 (green) was expressed in HeLa cells, a (a), b (b), c (c), p120 (d)-
catenin were stained by mouse anti-a, b, c, p120-catenin antibodies, respectively, followed by a ﬂuorescence-labeled anti-mouse IgG secondary antibody (red) and nuclei
were stained by DAPI (blue). FRMD5 and a, b, c, p120-catenin were all expressed at the contact points between cells and showed partly co-localization pattern, separately. (C)
Endogenous FRMD5 was localized to the cell–cell contacts. SW480 cells were stained with an anti-FRMD5 antibody (green). F-actin was stained by Phalloidin (red) and the
nuclei were stained by DAPI (blue), bar = 25 lm.
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several lung cancer cell lines by Western blot. High expression of
FRMD5 was observed in H1299, Wart, U1752 and U1906, and
low expression of FRMD5 was shown in A549 and U1810 cell lines
(Fig. 1E), suggesting that the level of FRMD5 in tumor is related to
the tumor classiﬁcation.3.2. The subcellular localization of FRMD5
In order to explore the biological function of FRMD5, the subcel-
lular localization of FRMD5 was observed. Firstly we overexpressed
GFP tagged FRMD5 in HeLa cells. After sorting by ﬂow cytometry,
the ﬂuorescence of GFP was nearly 100%. Then the localization of
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microscope (Fig. 2A and B). Although GFP-FRMD5 was found partly
located in cytoplasm, most of the ﬂuorescence was focused on the
cell–cell contact, as shown in the three arrows. Arrow I showed
that when cells did not form a cell–cell contact, GFP-FRMD5 was
not localized in the cell membrane. Arrow II showed that when
two GFP-positive cells formed a cell–cell contact, GFP-FRMD5
was located in the both cell membranes. Arrow III showed that
when a GFP-positive cell and a GFP-negative cell formed a cell–cell
contact, GFP-FRMD5 was located in membrane of the GFP-positive
cells. F-actin was stained by Phalloidin and nucleus was stained by
DAPI (Fig. 2A). These data showed that the subcellular localization
of FRMD5 is at the cell-cell contact. To further conﬁrm the associ-
ation of FRMD5 with a cell–cell contact, we detected whether
FRMD5 is colocalized with several components from tight junction
and adherens junction, such as Occludin, Claudin, ZO-1, ZO-2, E-
cadherin, a, b, c, and p120-catenin. Results showed that FRMD5
colocalized with adherens junction markers, including a, b, c and
p120-catenin but not tight junction markers, suggesting that
FRMD5 is localized in the adherens junction (Fig. 2B). Moreover,
endogenous localization of FRMD5 was also observed, and results
indicated that endogenous FRMD5 is partly localized in the cell–
cell contact (Fig. 2C).
3.3. FRMD5 interacts with p120-catenin through its C-terminal region
As FRMD5was colocalized with a, b, c, p120-catenin at the cell–
cell contact, it is possible that FRMD5 may form a complex with a,
b, c or p120-catenin. To this end, Co-IP experiments were per-
formed with an anti-Flag antibody, and results showed that Flag-
FRMD5 speciﬁcally interacts with p120-catenin (Fig. 3A), but not
with actin (data not shown), although some well-known FERM-
FA family proteins such as 4.1R, 4.1G, 4.1 N, 4.1B could interact
with actin [19]. It is reported that p120-catenin interacts with E-
cadherin, inhibiting its endocytosis and degradation [20]. P120-
catenin acts as a key regulator of cadherin switching. The expres-
sion of N-cadherin in epithelial cells could downregulate the levelFig. 3. FRMD5 interacts with p120-catenin through its C-terminal region. (A) Flag-FRMD5
then immunoprecipitated using an anti-Flag antibody. The immunoprecipitates were
respectively. Five percentage of cell lysates from the Co-IP experiment was loaded as inpu
a control rabbit IgG. Then, the immunoprecipitates were immunoblotted using the same a
separately. One percentage of cell lysates from the Co-IP experiment was loaded as inpu
transfected into H1299 cells as indicated and cell lysates were then immunoprecipitated
anti-Flag antibody or an anti-p120-catenin antibody. One percentage of cell lysates fromof E-cadherin by accelerating its degradation. A possible mecha-
nism could be a competition between N-cadherin and E-cadherin
to associate with p120-catenin [21]. Thus, to investigate the asso-
ciation of FRMD5, p120-catenin and E-cadherin, Co-IP assays were
performed in H1299 cells. Results showed that endogenous FRMD5
formed a tripartite complex with p120-catenin and E-cadherin
(Fig. 3B), indicating that FRMD5was involved in the adherens junc-
tion by interacting with p120-catenin and E-cadherin.
To map the binding regions between FRMD5 and p120-catenin,
FRMD5 was divided into two overlapped regions: the N-terminal
region, including 1–356 aa which contains FERM and FA domains,
and the C-terminal region, including 355–570 aa which does not
contain any known domain (Fig. 1A). Co-IP experiment showed
that both full length and the C-terminal region of FRMD5, but
not the N-terminal region, could interact with p120-catenin
(Fig. 3C).
3.4. FRMD5 regulates tumor progression
3.4.1. Knockdown of FRMD5 regulates the level of EMT markers
EPB41L5, another protein of FERM-FA family, is reported to
interact with p120-catenin through its N-terminal FERM domain
region. This interaction inhibits p120-catenin binding to E-cad-
herin, causing the degradation of E-cadherin [15]. Thus, a question
was raised whether the interaction between FRMD5 and p120-
catenin affects the degradation of E-cadherin. We synthesized
three siRNAs and two shRNAs targeting to FRMD5 mRNA. Results
showed that knockdown of FRMD5 downregulated E-cadherin
and upregulated Vimentin (Fig. 4A). Moreover, ﬁbronectin and
snail were upregulated in FRMD5-knocked down cells (Supple-
mentary Fig.), indicating that FRMD5 is involved in the progress
of EMT by interacting with p120-catenin and E-cadherin.
3.4.2. Knockdown of FRMD5 promotes cell migration and invasion in
H1299
As EMT is an important mechanism of tumor progression,
FRMD5 may regulate tumor progression by EMT. To compare theand Flag control vectors were transfected into H1299 cells and the cell lysates were
immunoblotted using an anti-Flag antibody, or an anti-p120-catenin antibody
t. (B) H1299 cell lysates were immunoprecipitated using an anti-FRMD5 antibody or
nti-FRMD5 antibody, an anti-E-cadherin antibody or an anti-p120-catenin antibody,
t. (C) Flag-FRMD5, Flag-FRMD5 N, Flag-FRMD5 C and the Flag control vectors were
using an anti-Flag antibody. The immunoprecipitates were immunoblotted using an
the Co-IP experiment was loaded as input.
Fig. 4. Knockdown of FRMD5 promotes cell migration and invasion in H1299. (A) a. Two H1299 cell lines stably transfected with FRMD5 shRNA and a control cell line were
established. Knockdown of FRMD5 decreased the protein level of E-cadherin and increased Vimentin. b. Three FRMD5 siRNAs and a control siRNA were transfected into
H1299 cells, the whole cell proteins were harvested 48 h later. Transiently knockdown of FRMD5 also down-regulate E-cadherin and up-regulate Vimentin at the protein
levels. (B) Knockdown of FRMD5 promoted cell migration in cell wound healing assay (n = 3, p < 0.001). (C) Knockdown of FRMD5 promoted cell migration in Transwell
migration assay (n = 18, p < 0.001). (D) Knockdown of FRMD5 promoted cell invasion in Transwell invasion assay (n = 18, p < 0.01). (E) Knockdown of FRMD5 promotes H1299
growth in vivo. a. One representative nude mouse in tumor growth experiment. Left subaxillary fat pad was injected with 4  106 H1299 sh-FRMD5 cells and the same
amount of sh-NC cells were injected to the right site. b. The tumors dissected from each mouse. The upper panel of tumors was dissected from sh-NC H1299 cells, and the
lower panel of tumors was dissected from sh-FRMD5 H1299 cells. Six mice were used in this experiment. c. The average weight of the tumors in b was given. Statistics using
paired t test showed P < 0.001.
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cells, both wound healing and Transwell migration assays were
performed. Result showed that knockdown of FRMD5 accelerated
the velocity of wound closure (Fig. 4B), indicating that FRMD5
inhibits the lateral migration of tumor cells. In addition, to observe
the effect of FRMD5 on the vertical migration of tumor cells, Trans-
well migration assay was performed. Results indicated that knock-
down of FRMD5 promoted the vertical migration of tumor cells
(Fig. 4C). Moreover, the invasive ability of tumor cells was also de-
tected by Transwell invasion assays. As shown in Fig. 4D, an in-
creased invasion ability was observed in H1299 sh-FRMD5 cells
compared to the control cells. Taken together, these results indi-
cated that knockdown of FRMD5 promotes the mobility of tumor
cells.
To further identify the role of FRMD5 in vivo, the tumorigenesis
assay was carried out. In this experiment, 4  106 cells (H1299 sh-
FRMD5 and H1299 sh-NC) were planted in the armpit of six nude
mice (left for control and right for H1299 sh-FRMD5). After three
weeks, both sides of the six mice formed visible tumors. We
weighted the tumor and performed statistical analysis using paired
t-test. The result showed that a signiﬁcant difference existed be-
tween the two groups (Fig. 4F). The data indicated that FRMD5
inhibits tumor formation in vivo. Collectively, these data suggested
that FRMD5 plays an inhibitory role during tumor progression.
4. Discussion
The biological function of FRMD5 remained unknown before
this study. As FRMD5 contains intact FERM and FA domain, it is
classiﬁed into FERM-FA family. This family includes a well-knownprotein 4.1R, which plays an important role in maintaining the
shape and the membrane mechanical properties of the red blood
cells. Mutant or loss expression of 4.1R has been reported in many
tumors, so did in 4.1B and FRMD3. However, other members of the
family, ehm2 and EPB41L5, have been reported playing opposite
roles in tumor progress. Here, we cloned the cDNA encoding
FRMD5 for the ﬁrst time. FRMD5 was mainly found localized to
the cell–cell contact, similar to other members of the FERM super-
family like 4.1B, ezrin, radixin and moesin [22]. As E-cadherin/a, b,
p120-catenin are well-known adherens junction components [23],
partially colocalization of FRMD5 with a, b, c, p120-catenin indi-
cated that FRMD5might be a component of adherens junction. Fur-
ther, we found that FRMD5 interactes with p120-catenin through
its C-terminal region, and this interaction might enhance the bind-
ing of p120-catenin to E-cadherin, preventing E-cadherin from
endocytosis and degradation. It is interesting that EPB41l5, another
protein of FERM-FA family, sharing the domain organization with
FRMD5, could interact with p120-catenin through its N-terminal
FERM domain, and inhibits the binding of p120-catenin to E-cad-
herin that results in the degradation of E-cadherin [23]. As the
binding region of p120-catenin to EPB41L5 was the same as the re-
gion that binds to E-cadherin, it is presumed that the EPB41L5
competed with E-cadherin to bind to p120-catenin. In our study,
although FRMD5 interacts with p120-catenin, the role of this inter-
action may enhance the binding of p120-catenin with E-cadherin,
and to form a FRMD5–p120-catenin–E-cadherin complex to stabi-
lize adherens junction.
In conclusion, FRMD5 is functionally identiﬁed as a novel tumor
suppressive molecule that may stabilizes cell–cell contact and reg-
ulates tumor progression.
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